Hemodynamic effects of reboxetine in healthy male volunteers

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 282-287

  Denolle, Thierry ^a   Pellizzoni, Cinzia ^b   Jannuzzo, M Gabriella ^b   Poggesi, Italo ^b  

^a Biotrial SA   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

REBOXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TOLERABILITY; ENANTIOMER; HEART RATE; HEMODYNAMICS; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDING; SUPINE POSITION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HALF-LIFE; HEART RATE; HUMANS; MALE; MORPHOLINES; POSTURE; REFERENCE VALUES; STEREOISOMERISM; TIME FACTORS;

EID: 0032862005     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70036-6     Document Type: Article

References (19)

1. 1. Melloni P, Carniel G, Della Torre A, Bonsignori A, Buonamici M, Pozzi O, et al. Potential antidepressant agents, α-aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem Clin Ther 1984;19:235-42.
2. 2. Riva M, Brunello N, Rovescalli AC, Galimberti R, Carfagna N, Carminati P, et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioral and biochemical studies. J Drug Dev 1989;1:243-53.
3. 3. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11(suppl):S9-15.
4. 4. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997;11(suppl):S33-7.
5. 5. Melloni P, Della Torre A, Lazzari E, Mazzini G, Meroni M. Configurational studies on 2-[α-(2-ethoxyphenoxy)benzyl]morpholine FCE 20124. Tetrahedron 1985;41:1393-9.
6. 6. Dostert P, Strolin Benedetti M, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997;7(suppl 1):S23-35.
7. 7. Strolin Benedetti M, Frigerio E, Tocchetti P, Brianceschi G, Castelli MG, Pellizzoni C, et al. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 1995;7:285-9.
8. 8. Frigerio E, Benecchi A, Brianceschi G, Pellizzoni C, Poggesi I, Strolin Benedetti M, et al. Pharmacokinetics of reboxetine enantiomers in the dog. Chirality 1997;9:303-6.
9. 9. Strolin Benedetti M, Pellizzoni C, Poggesi I, Dostert P, Dubini A, Bosc M, et al. Pharmacokinetics of reboxetine enantiomers in healthy volunteers [abstract P13.21.17]. XIIth International Congress of Pharmacology, Montreal, Quebec, July 24-30, 1994.
10. 10. Frigerio E, Pianezzola E, Strolin Benedetti M. Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reverse-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl)ethyl chloroformate. J Chromatogr 1994;A660:351-8.
11. 11. Wong EHF, Graveel CR, Kagey ML, Cafagna N, Smith MW. Pharmacological-selectivity of reboxetine: a selective noradrenaline reuptake inhibitor (NARI). Presented at the meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 8-12, 1997.
12. 12. Rechlin T. The effect of amitriptyline, doxepin, fluvoxamine and paroxetine treatment on heart rate variability. J Clin Psychopharmacol 1994;14:392-5.
13. 13. Rudorfer MV, Young RC. Anticholinergic effects and plasma desipramine levels. Clin Pharmacol Ther 1980;28: 703-6.
14. 14. Szabadi E, Gaszner P, Bradshaw CM. The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitriptyline and desipramine in human volunteers. Br J Psychiatry 1980;137:433-9.
15. 15. Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992;6 (suppl 4):59-64.
16. 16. Hamilton MJ, Smith PR, Peck AW. Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy male volunteers. Br J Clin Pharmacol 1983;15:367-74.
17. 17. Roose SP, Glassman AH, Giardina EGV, Johnson LL, Walsh BT, Bigger JT. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987;7:247-51.
18. 18. Edwards DMF, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995;16:443-60.
19. 19. Pellizzoni C, Poggesi I, Jørgensen NP, Edwards DMF, Paus E, Strolin Benedetti M. Pharmacokinetics of reboxetine in healthy volunteers: single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996;17:623-33.